- |||||||||| dacarbazine / Generic mfg., doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Trial completion: Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease (clinicaltrials.gov) - Dec 5, 2011 P2, N=35, Completed, Active, not recruiting --> Completed
- |||||||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment closed, Metastases: Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function (clinicaltrials.gov) - Nov 13, 2011 P2, N=40, Active, not recruiting, N=34 --> 24 Recruiting --> Active, not recruiting
- |||||||||| Trial completion, Combination therapy: BIG 02/98 Docetaxel - Breast Cancer (clinicaltrials.gov) - Nov 8, 2011
P3, N=2887, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| mitomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Surgery: Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2011 P1, N=11, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| vinorelbine tartrate / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy: Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Sep 28, 2011 P1, N=29, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 25, 2011 P2, N=60, Active, not recruiting,
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, New P2 trial, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 9, 2011 P2, N=100, Active, not recruiting,
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 9, 2011 P3, N=1400, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting
|